Spectrum Pharmaceuticals Inc. (SPPI) and TG Therapeutics Inc. (NASDAQ:TGTX) Comparison side by side – MS Wkly

Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) and TG Therapeutics Inc. (NASDAQ:TGTX) compete with each other in the Biotechnology sector. We will analyze and contrast their dividends, analyst recommendations, profitability, risk, institutional ownership, earnings and valuation.

Valuation & Earnings

In table 1 we can see Spectrum Pharmaceuticals Inc. and TG Therapeutics Inc.s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 shows us the net margins, return on assets and return on equity of both companies.

Volatility & Risk

Spectrum Pharmaceuticals Inc. is 154.00% more volatile than Standard and Poors 500 because the company has a beta of 2.54. From a competition point of view, TG Therapeutics Inc. has a 2.32 beta which is 132.00% more volatile compared to Standard and Poors 500.

Analyst Ratings

The table delivered features the ratings and recommendations for Spectrum Pharmaceuticals Inc. and TG Therapeutics Inc.

Meanwhile, TG Therapeutics Inc.s average price target is $20, while its potential upside is 284.62%.

Institutional and Insider Ownership

Roughly 75.6% of Spectrum Pharmaceuticals Inc. shares are held by institutional investors while 59% of TG Therapeutics Inc. are owned by institutional investors. Insiders held roughly 1.3% of Spectrum Pharmaceuticals Inc.s shares. Insiders Comparatively, held 0.4% of TG Therapeutics Inc. shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Spectrum Pharmaceuticals Inc. had bearish trend while TG Therapeutics Inc. had bullish trend.

Summary

On 8 of the 10 factors Spectrum Pharmaceuticals Inc. beats TG Therapeutics Inc.

Spectrum Pharmaceuticals, Inc. develops and commercializes oncology and hematology drug products. The company markets six drug products, including FUSILEV for patients with metastatic colorectal cancer and rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor to treat patients with relapsed or refractory PTCL; ZEVALIN injection for patients with follicular non-Hodgkins lymphoma; MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ injection for patients with relapsed or refractory PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients. It is also developing ROLONTIS for chemotherapy-induced neutropenia; QAPZOLA for intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer; and POZIOTINIB for treating breast and lung cancer. The company sells its drugs through a direct sales force in the United States; and through distributors in Europe. Spectrum Pharmaceuticals, Inc. has licensing and development agreement with Cell Therapeutics, Inc.; license agreement with Merck & Cie AG, Sloan-Kettering Institute, and Cydex Pharmaceuticals, Inc.; development and commercialization collaboration agreement with Allergan, Inc.; collaboration agreement with Nippon Kayaku Co., LTD.; licensing and collaboration agreement with Onxeo DK; and co-development and commercialization agreement with Hanmi Pharmaceutical Company. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Henderson, Nevada.

TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases primarily in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory non-Hodgkins lymphoma and chronic lymphocytic leukemia. The company also develops TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency to the delta isoform and high selectivity over the alpha, beta, and gamma isoforms, as well as for hematologic malignancies. In addition, it develops a pre-clinical program to develop interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors; bromodomain and extra terminal (BET) inhibitor program in the field of hematological malignancies; and anti-PD-L1 and anti-GITR antibody research programs that are in pre-clinical development stage in the field of hematological malignancies. The company has license agreements with LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, and Ildong Pharmaceutical Co. Ltd. for the development and commercialization of TG-1101 (ublituximab); Rhizen Pharmaceuticals, SA for the development and commercialization of TGR-1202; Ligand Pharmaceuticals Incorporated for the development and commercialization of IRAK4 inhibitor technology; Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs; and Jubilant Biosys for the development and commercialization of BET inhibitor program. TG Therapeutics, Inc. is headquartered in New York, New York.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

View post:
Spectrum Pharmaceuticals Inc. (SPPI) and TG Therapeutics Inc. (NASDAQ:TGTX) Comparison side by side - MS Wkly